David Apelian is CEO of Eiger BioPharmaceuticals, Inc.. Currently has a direct ownership of 11,000 shares of EIGR, which is worth approximately $139,150. The most recent transaction as insider was on Aug 16, 2022, when has been sold 5,000 shares (Common Stock) at a price of $9.81 per share, resulting in proceeds of $49,050. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 11K
0% 3M change
0% 12M change
Total Value Held $139,150

David Apelian Transaction History

Date Transaction Value Shares Traded Shares Held Form
Aug 16 2022
SELL
Open market or private sale
$49,050 $9.81 p/Share
5,000 Reduced 31.25%
11,000 Common Stock
Mar 11 2022
BUY
Grant, award, or other acquisition
-
6,000 Added 27.27%
16,000 Common Stock
Mar 12 2021
BUY
Grant, award, or other acquisition
-
5,000 Added 33.33%
10,000 Common Stock
DA

David Apelian

CEO
Palo Alto, CA

Track Institutional and Insider Activities on EIGR

Follow Eiger BioPharmaceuticals, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells EIGR shares.

Notify only if

Insider Trading

Get notified when an Eiger Bio Pharmaceuticals, Inc. insider buys or sells EIGR shares.

Notify only if

News

Receive news related to Eiger BioPharmaceuticals, Inc.

Track Activities on EIGR